Hermes Belt Gold Buckle
Progression of CardioCel with cellular therapies programme
"The initial target is to get CardioCel into 15 key centres in Europe and in the US and as we scale up our manufacturing we will increase the number of new centres coming on stream and continue to grow our revenue." Mr. Rodne said
Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential such as Herpes and Human Papillomavirus.
Mr. Lee Rodne.
For more information, please contact:
CardioCel into 15 key centers in Europe
"We've had a very encouraging initial launch period for CardioCel and the key for us during this early phase is centre penetration" said Mr. Rodne. "This will provide the base to continue to grow revenue for the company as surgeons begin to experience the benefits of using CardioCel first hand for the repair and reconstruction of cardiovascular defects in both children and adults" he added.
In addition, the Company is seeking marketing approvals for CardioCel in other jurisdictions and expansion of use for CardioCel, not only for additional cardiovascular applications, but also for other areas of surgical repair. The Company will make additional updates on these planned programmes during the 2014/15 financial year.
Growing revenues for the group
Complete the Lv Belt Uk
Initial Asian market approval for CardioCel
preclinical HPV therapeutic vaccine programme
CardioCel into 15 key centers in the US
manufacturing site in Western Australia to provide manufacturing capability for the global supply of CardioCel and it is anticipated that production of CardioCel for the US market will commence in July this year.
Initiation of CardioCel market expansion studies
The Company currently has 12 key centres in Europe using the product and has received sales orders from US key centres earlier than scheduled.
The past 12 months have been very successful for Admedus and it is anticipated that this trend will continue for the next 12 months as we focus our activities to achieve the following milestones:
Over the past 12 months Admedus, in collaboration with Professor Ian Frazer and his team, entered into a Phase I study with a Herpes simplex virus (HSV 2) therapeutic vaccine. The Company released interim positive Phase I results earlier this year and is expecting to release additional data from the study in the next quarter once final assay analysis is completed. The positive interim results mean the programme will progress into Phase II, with the team currently finalising details for the study which is scheduled to be initiated by the end of 2014.
Initiation of the Herpes (HSV 2) Phase II clinical study
Admedus End Of Financial Year
At the beginning of 2014 Admedus acquired a state of the art Louis Vuitton Belt Receipt
Admedus (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research development through clinical development as well as sales, marketing and distribution.
Admedus (ASX: AHZ) today announced an update on activities across the Group. The company highlighted that total income, including revenue grants and other income, for the Group is expected to be over to $9M for this Hermes Belt Gold Buckle financial year, up from the previous year, with a closing cash balance of over $20M. These results place the Company in a strong position to progress towards our key milestones of growing revenue and progressing our platform technologies in regenerative medicine and next generation immunotherapies.
Expansion of the regenerative tissue portfolio
"The past 12 months have been extremely successful, with European and US marketing clearance for our lead regenerative tissue product CardioCel and the completion of the HSV 2 vaccine Phase I study" said Admedus CEO Gucci Belt Silver And Black
Hermes Belt Gold Buckle
Hermes Belts 2018
Lv Belt Blue
Lv Womens Belt
Ferragamo Belts For Women
Louis Vuitton Belt Brown Silver Buckle
Hermes Belt Price
Nike Hats Black
New Era 59fifty Low Crown
Chicago Bulls Hats For Girls
Ferragamo Belt New
Gucci Belt Tiger Print
New Era Nba Snapbacks
Diesel Belts Prices
Gucci Belt Black Red And Green
Jordan Hat Black And Red